A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-25

Study Completion Date

2023-03-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment naïve or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

NCT07169565

Waldenström Macroglobulinemia (WM)

NOT_YET_RECRUITING PHASE1

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

NCT04061512

Waldenstrom Macroglobulinemia

RECRUITING PHASE2/PHASE3

Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

NCT03630042

Waldenstrom Macroglobulinemia

COMPLETED PHASE2

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM

NCT05914662

Waldenstrom Macroglobulinemia

RECRUITING PHASE2

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

NCT04994626

DLBCL MYD88 Gene Mutation CD79A Gene Mutation +3 more

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Waldenstrom Macroglobulinemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ibrutinib + Rituximab

Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.

Group Type EXPERIMENTAL

Ibrutinib

Intervention Type DRUG

Ibrutinib 420 mg will be administered orally.

Rituximab

Intervention Type DRUG

Rituximab 375 mg/m\^2 will be administered intravenously.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ibrutinib

Ibrutinib 420 mg will be administered orally.

Intervention Type DRUG

Rituximab

Rituximab 375 mg/m\^2 will be administered intravenously.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PCI-32765

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia (WM) in accordance with the consensus panel of the second International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
* Japanese participants with treatment naïve or relapsed/refractory WM
* Measurable disease defined as serum monoclonal immunoglobulin M (IgM) greater than (\>) 0.5 gram per deciliter (g/dL)
* Symptomatic disease, requiring treatment
* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (\<=) 2
* Hematology and biochemical values within protocol-defined limits
* Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective methods of contraception while taking study drug. Women of childbearing potential must be practicing a highly effective, preferably user independent method of birth control during treatment with any drug in this study and for up to 12 months after the last dose of rituximab, 1 month after last dose of ibrutinib. Male participants must use an effective barrier method of contraception during the study and after receiving the last dose of ibrutinib, and for up to 12 months after last dose of rituximab if sexually active with a female of childbearing potential
* Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study. Participants must be willing and able to adhere to the prohibitions and restrictions specified in this protocol
* Must be willing and able to adhere to the lifestyle restrictions specified in this protocol

Exclusion Criteria

* Involvement of the central nervous system by WM
* Prior exposure to ibrutinib or other Bruton's Tyrosine Kinase (BTK) inhibitors
* Rituximab treatment within the last 12 months before the first dose of study intervention
* Received any WM-related therapy \<=30 days prior to first administration of study treatment
* Plasmapheresis less than (\<) 35 days prior to the initiation of study drug, except when at least one serum IgM central assessment was performed during the screening period and was \>35 days from the most recent plasmapheresis procedure
* History of other malignancies
* Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
* Infection requiring systemic treatment that was completed \<=14 days before the first dose of study drug
* Currently active, clinically significant Child-Pugh Class B or C hepatic impairment
* Inability or difficulty swallowing capsules, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function
* Stroke or intracranial hemorrhage within 12 months prior to enrollment
* Currently active, clinically significant cardiovascular disease
* Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
* Infection with human immunodeficiency virus (HIV) or active infection with hepatitis B or hepatitis C virus
* Major surgery within 4 weeks of first dose of study drug
* Lactating or pregnant
* Male participants who plan to father a child while enrolled in this study or within 3 months after the last dose of ibrutinib, and within 12 months after last dose of rituximab
* Any contraindication to ibrutinib or rituximab including hypersensitivity to the active substance or to any of the excipients of ibrutinib or rituximab per local prescribing information
* Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before the planned first dose of study intervention or is currently enrolled in an investigational study
* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg \[for example\], compromise the wellbeing) or that could prevent, limit, or confound the protocol-specified assessments
* Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No